In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Late-stage round generates $36.2mm for DFine

Executive Summary

DFine Inc. (developing minimally invasive devices for vertebral fractures) has brought in $36.2mm through a late-stage financing led by first-time Split Rock Partners. Fellow new backer OrbiMed, returning shareholders Prospect Venture Partners, Vanguard Ventures, BBT Fund/Apothecary Capital, and Highland Capital Management, and private investors also participated. A member of Split Rock and OrbiMed will join the company's board. The funds will be used for ongoing commercialization of its StabiliT vertebral augmentation system.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Medical Devices
    • Biomaterials
    • Radiofrequency Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies